Thus, we analyzed data from the 2001 Behavioral Risk Factor Surveillance System (BRFSS), a large, nationally representative telephone survey, to address some of the limitations of earlier studies. We sought to determine whether, after adjusting for potential confounders including health status, self-reported rates of completion of evidence-based colorectal cancer screening decrease between the ages of 50 and 80 years, as would be predicted based on ageism bias. We also compared age-related patterns of color
Adjusted predicted marginal cancer-screening percentages by age-group are shown in Table 1 and illustrated in the supplemental figure, which is available online at . Colorectal cancer screening increased until age 70 to 74 years and declined after the age of 80 years. Similar age trends were observed for fecal occult blood testing alone (the dominant colorectal screening modality), when a 1-year interval was used to define screening, and in an analysis confined to those with health insurance (data not shown
24. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. 351:337-345, 2004.
All comorbidity measures segregate study participants into those who are healthier and those are less healthy. The objective of this review is to examine how well researchers can expect to have achieved this goal, given the variable axis for which they are measuring comorbidity, the comorbidity measure they select, and the analytic method they choose.
27. Green EM, Sargent DJ, Goldberg RM, et al: Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741 (abstract 264O). 15(suppl 3):70, 2004.